- Home
- LRMR vs BME Comparison
LRMR vs BME Comparison
Compare LRMR & BME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LRMR | BME |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.8M | 511.9M |
| IPO Year | 2014 | 2005 |
Fundamental Metrics
Financial Performance| Metric | LRMR | BME |
|---|---|---|
| Price | $3.47 | $40.94 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $16.50 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 45.0K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,816.14 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.26 | $35.03 |
| 52 Week High | $6.42 | $42.74 |
Technical Indicators
Market Signals| Indicator | LRMR | BME |
|---|---|---|
| Relative Strength Index (RSI) | 49.57 | 66.10 |
| Support Level | $3.10 | $40.55 |
| Resistance Level | $3.74 | $42.55 |
| Average True Range (ATR) | 0.20 | 0.61 |
| MACD | 0.06 | 0.14 |
| Stochastic Oscillator | 81.29 | 96.50 |
Price Performance
Historical ComparisonAbout LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return and income mainly through long-term capital appreciation. The Trust invests the majority of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives with exposure to the health sciences industry.